Ultimovacs ASA
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs ASA (ULTI) - Net Assets
Latest net assets as of December 2024: Nkr82.67 Million NOK
Based on the latest financial reports, Ultimovacs ASA (ULTI) has net assets worth Nkr82.67 Million NOK as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr115.86 Million) and total liabilities (Nkr33.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr82.67 Million |
| % of Total Assets | 71.35% |
| Annual Growth Rate | 1.09% |
| 5-Year Change | -83.07% |
| 10-Year Change | N/A |
| Growth Volatility | 78.2 |
Ultimovacs ASA - Net Assets Trend (2016–2024)
This chart illustrates how Ultimovacs ASA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ultimovacs ASA (2016–2024)
The table below shows the annual net assets of Ultimovacs ASA from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr82.67 Million | -70.41% |
| 2023-12-31 | Nkr279.39 Million | -37.82% |
| 2022-12-31 | Nkr449.35 Million | -24.24% |
| 2021-12-31 | Nkr593.15 Million | +21.45% |
| 2020-12-31 | Nkr488.38 Million | +9.84% |
| 2019-12-31 | Nkr444.63 Million | +178.06% |
| 2018-12-31 | Nkr159.90 Million | -3.95% |
| 2017-12-31 | Nkr166.48 Million | +119.57% |
| 2016-12-31 | Nkr75.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ultimovacs ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 99264200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Nkr1.15 Billion | 1385.14% |
| Total Equity | Nkr82.67 Million | 100.00% |
Ultimovacs ASA Competitors by Market Cap
The table below lists competitors of Ultimovacs ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alphageo (India) Limited
NSE:ALPHAGEO
|
$6.19 Million |
|
NORTHROP GRUMMAN - Dusseldorf Stock Exchang
DU:NTH
|
$6.19 Million |
|
Churchill Resources Inc.
PINK:CRICF
|
$6.19 Million |
|
MITSUI FUDOSAN LOG.PARK
F:85L
|
$6.20 Million |
|
Global Power Solutions Corp.
V:PWER
|
$6.19 Million |
|
S&S Healthcare Holding Ltd.
TWO:4198
|
$6.19 Million |
|
Emmbi Industries Limited
NSE:EMMBI
|
$6.19 Million |
|
Outback Goldfields Corp
OTCQB:OZBKF
|
$6.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ultimovacs ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 279,392,000 to 82,669,000, a change of -196,723,000 (-70.4%).
- Net loss of 201,061,000 reduced equity.
- Other factors increased equity by 4,338,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-201.06 Million | -243.21% |
| Other Changes | Nkr4.34 Million | +5.25% |
| Total Change | Nkr- | -70.41% |
Book Value vs Market Value Analysis
This analysis compares Ultimovacs ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.99x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 5.29x to 5.99x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Nkr2.72 | Nkr14.40 | x |
| 2017-12-31 | Nkr5.98 | Nkr14.40 | x |
| 2018-12-31 | Nkr5.74 | Nkr14.40 | x |
| 2019-12-31 | Nkr15.96 | Nkr14.40 | x |
| 2020-12-31 | Nkr15.26 | Nkr14.40 | x |
| 2021-12-31 | Nkr17.33 | Nkr14.40 | x |
| 2022-12-31 | Nkr13.06 | Nkr14.40 | x |
| 2023-12-31 | Nkr8.12 | Nkr14.40 | x |
| 2024-12-31 | Nkr2.40 | Nkr14.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ultimovacs ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -243.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.40x
- Recent ROE (-243.21%) is below the historical average (-56.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -38.22% | 0.00% | 0.00x | 1.09x | Nkr-36.56 Million |
| 2017 | -19.72% | 0.00% | 0.00x | 1.07x | Nkr-49.48 Million |
| 2018 | -34.57% | 0.00% | 0.00x | 1.19x | Nkr-71.27 Million |
| 2019 | -13.76% | 0.00% | 0.00x | 1.08x | Nkr-105.63 Million |
| 2020 | -24.68% | 0.00% | 0.00x | 1.08x | Nkr-169.39 Million |
| 2021 | -27.77% | 0.00% | 0.00x | 1.11x | Nkr-224.04 Million |
| 2022 | -37.34% | 0.00% | 0.00x | 1.13x | Nkr-212.73 Million |
| 2023 | -67.73% | 0.00% | 0.00x | 1.25x | Nkr-217.18 Million |
| 2024 | -243.21% | 0.00% | 0.00x | 1.40x | Nkr-209.33 Million |
Industry Comparison
This section compares Ultimovacs ASA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $67,094,196
- Average return on equity (ROE) among peers: -121.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ultimovacs ASA (ULTI) | Nkr82.67 Million | -38.22% | 0.40x | $6.19 Million |
| Arctic Bioscience AS (ABS) | $287.28 Million | -11.84% | 0.14x | $3.71 Million |
| Aqua Bio Technology ASA (ABTEC) | $8.32 Million | -176.71% | 0.95x | $7.08 Million |
| Arcticzymes Technologies ASA (AZT) | $68.08 Million | -30.08% | 0.26x | $76.32 Million |
| Circa Group AS (CIRCA) | $41.74 Million | -16.77% | 0.13x | $3.57 Million |
| Circio Holding ASA (CRNA) | $-98.54 Million | 0.00% | 0.00x | $16.90 Million |
| Exact Therapeutics AS (EXTX) | $42.24 Million | -35.10% | 0.23x | $3.19 Million |
| Lytix Biopharma AS (LYTIX) | $107.89 Million | -87.37% | 0.36x | $32.31 Million |
| PCI Biotech Holding ASA (PCIB) | $57.40 Million | -95.98% | 0.11x | $432.13K |
| SoftOx Solutions AS (SOFTX) | $16.01 Million | -444.47% | 3.86x | $12.63 Million |
| Thor Medical ASA (TRMED) | $140.52 Million | -314.06% | 1.11x | $48.68 Million |